Showing papers by "Gordon R. Bernard published in 1986"
TL;DR: Until success is achieved, supportive intensive care with diligent attention to oxygen and ventilator management, infection control, and fluid therapy will be the mainstay of treatment for ARDS.
40 citations
Journal Article•
TL;DR: N-acetylcysteine (NAC) inhibits the in vivo effects of endotoxemia in chronically instrumented unanesthetized sheep and functions as a free radical scavenger in vitro.
Abstract: Endotoxemia is used as a model of the adult respiratory distress syndrome in chronically instrumented awake sheep. The toxic effects of endotoxin may be mediated through inflammatory cells and the release of toxic oxidants. N-acetylcysteine (NAC) inhibits the in vivo effects of endotoxemia in chronically instrumented unanesthetized sheep. NAC also functions as a free radical scavenger in vitro. It is possible that the protective effects of pretreatment with NAC result from NAC's ability in vivo to protect against local oxidant injury.
4 citations
Journal Article•
TL;DR: Even with advances in treating established ARDS, careful attention toward prevention and day-to-day management of ARDS patients will be required to reduce the excessive mortality.
Abstract: ARDS is a severe disorder affecting over 150,000 patients per year in the United States alone. The syndrome has multiple etiologies that to a larger extent determine the 60% to 70% mortality associated with the process. In spite of intense research, there is still no specific therapy of proven benefit that we can offer patients. Supportive measures designed to keep the patient alive long enough to allow the pulmonary lesion to heal are the mainstay of therapy. These measures are constantly being improved and increasingly require invasive high technology. Even with advances in treating established ARDS, careful attention toward prevention and day-to-day management of ARDS patients will be required to reduce the excessive mortality.
2 citations